CN Patent

CN111821302A — 用于联合治疗软骨肉瘤的喹啉类化合物

Assigned to Chia Tai Tianqing Pharmaceutical Group Co Ltd · Expires 2020-10-27 · 6y expired

What this patent protects

本发明属于医药领域，提供用于联合治疗软骨肉瘤的喹啉类化合物或其药学上可接受的盐，具体涉及治疗有效量的1‑[[[4‑(4‑氟‑2‑甲基‑1H‑吲哚‑5‑基)氧基‑6‑甲氧基喹啉‑7‑基]氧基]甲基]环丙胺或其药学上可接受的盐与第二治疗剂联合在制备用于治疗软骨肉瘤的联用药物中的应用。

USPTO Abstract

本发明属于医药领域，提供用于联合治疗软骨肉瘤的喹啉类化合物或其药学上可接受的盐，具体涉及治疗有效量的1‑[[[4‑(4‑氟‑2‑甲基‑1H‑吲哚‑5‑基)氧基‑6‑甲氧基喹啉‑7‑基]氧基]甲基]环丙胺或其药学上可接受的盐与第二治疗剂联合在制备用于治疗软骨肉瘤的联用药物中的应用。

Drugs covered by this patent

Patent Metadata

Patent number
CN111821302A
Jurisdiction
CN
Classification
—
Expires
2020-10-27
Drug substance claim
No
Drug product claim
No
Assignee
Chia Tai Tianqing Pharmaceutical Group Co Ltd
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.